Kluyvera ascorbata as a Pathogen in Adults and Children: Clinical Features and Antibiotic Susceptibilities in a Single Center Study.

To approach the clinical characteristics of rare Kluyvera ascorbata infection, we reviewed the medical records of patients from whom K. ascorbata was isolated from 2010 to 2016, and conducted a systematic review of the English and Spanish literature in PubMed for reports of K. ascorbata infection in humans from 1971 to 2018. A total of 43 cases (24 adults and 19 children) were enrolled: three in our hospital and 40 from literature review. The urinary tract was the most common site of infection (44.2%, 19/43), followed by the bloodstream (27.9%, 12/43). There was no significant difference in frequency of urinary tract infections (50% vs 36.8%; P=0.388) and bloodstream infections (25% vs 31.6%; P=0.633) in adults and children. Seventeen (60.7%, available in 28 of 43 cases) had nosocomial or healthcare-associated infections: 72.7% among children and 60% among adults. Superinfection developed in 20% (6 in 30 cases). Overall mortality was 12.1%. The antimicrobial agents mainly used in these 43 cases were third-generation cephalosporin, cefepime, piperacillin-tazobactam, ciprofloxacin, amikacin, and carbapenem. Most strains were resistant to ampicillin and first- and second-generation cephalosporins. K. ascorbata is rare but significant clinical pathogen in adults and children.